(CercleFinance.com) – Pfizer announced on Monday that it had decided to end the clinical program concerning vupanorsen, an experimental drug against cardiovascular diseases discovered by its partner Ionis Pharmaceuticals.
The American biopharmaceutical giant says it made its decision following the disclosure of phase 2b data in hypertriglyceridemia (increased triglycerides in the blood).
While the trial did meet its primary endpoint, Pfizer says the results are insufficient to warrant continuation of the program, which it supported under the licensing agreement with Ionis in 2019.
It should also be noted that the Swedish company Alex Therapeutics announced on Monday that it was going to join forces with Pfizer in the field of personalized therapies.
The partnership, which is to encompass areas such as artificial intelligence, software and psychology – will initially focus on the German market.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
